Safety, Tolerability, and Pharmacokinetics of HSK21542 in Healthy Volunteers

Summary

This is a A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of a kappa receptor agonist HSK21542 in Healthy Volunteers. The study will enroll approximately 50 adults. The anticipated study duration will be up to 6 months.

Timeline

Start

2020-07-02

Primary completion

2020-12-08

Completion

2021-01-05

Drugs

Indications